Heat-treated gut supplement LpD3.5 for older adults with mild cognitive impairment
Tests LpD3.5 capsules against placebo in older adults with mild cognitive impairment.
Key facts
- Who runs it
- University of South Florida
- Where
- Tampa, United StatesSee the site
- Trial code
- Registry title
- LpD3.5 Intervention Study in Older Adults- LISA-I Trial
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 15 people, planned
- Started
- 3 Mar 2026
- Planned end
- 15 Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- LpD3.5
- Placebo
- Record updated
- 31 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 60 or older with mild cognitive impairment (mild memory and thinking problems). They take LpD3.5 capsules or placebo capsules for 60 days.
- Age
- 60 years and older. Study partners must also be 60 years or older.
- Sex
- All sexes.
- Disease stage
- Mild cognitive impairment diagnosed by a doctor, with a Montreal Cognitive Assessment (MoCA) score between 18 and 25.
- Earlier treatment
- No antibiotic use in the past 30 days. No history of fecal microbiota transplantation (transfer of stool bacteria). No cancer treatment in the past 5 years.
- Biomarker or test result
- LBP ≥ 30 μg/mL in plasma (a blood marker linked to a leaky gut).
Main reasons for not taking part
- Brain or gut surgery in the past 5 years that affected thinking
- Bowel diseases such as inflammatory bowel disease, Crohn's disease, acid reflux or C. difficile infection
- Cancer or cancer treatment in the past 5 years
- Nervous system disorders like epilepsy, Parkinson's disease or ALS
- Pregnancy, being a prisoner, or serious or terminal illness
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age 60 years and above; (ii) physician based clinically diagnosed MCI and the Montreal Cognitive Assessment (MoCA) score between 18 and 25; iii) LBP ≥ 30 μg/mL in plasma, and (iv) willing to sign informed consent, take intervention regimen, follow study team guidelines and donate sam-ples, as instructed by the study team; and (iv) live with a partner or care giver
- Study partners in this study must meet the following inclusion criteria:
- Be 60 years or older
- Willingness to participate in the study and provide consent
- Ability to have regular contact with the participant(s)
- Be knowledgeable about the participant's health, memory, and daily activities
- Communicate effectively in English
Who cannot take part
- Brain and gut related surgery within the past 5 years that affected cognitive function: This information will be collected during the initial telephonic screening through an eligibility checklist. (ii) diagnosis of inflammatory bowel disease, ulcerative colitis, Crohn's disease, acid reflux, gastroesophageal reflux disease, Clostridium difficile infection, or any other gastrointestinal disease that might significantly change the microbiome, gut permeability, and inflammation: Participants will be asked about these diagnoses during the telephonic screening, and responses will be documented : Participants will be asked about these diagnoses during the telephonic screening, and responses will be documented. (iii) history of fecal microbiota transplantation and small intestinal bacterial growth: These conditions will also be screened via the initial eligibility questionnaire ad-ministered during the pre-screening phone interview. (iv) history of cancer or cancer treatment in past 5 years: Participants will be asked to report any history of cancer or treatment during the tele-phonic screening (v) nausea, vomiting, food poisoning, constipation, or diarrhea and/or antibiotic use in the past 30 days; These symptoms will be captured via a brief symptom checklist completed at the time of recruitment as well as on-site at the initial study visit. (vi) heavy consumption of pro-biotics, yogurt, or other fermented food (>4 servings per day): Questionnaire on probiotic yogurt, or other fermented food will be administered during the initial screening by telephonic talk as well as on-site visit to capture this information.(vii) critical or terminal illnesses; (viii) having neurological disorders like epilepsy, Parkinson's disease and Amyotrophic lateral sclerosis: These conditions will be assessed via direct questioning during the telephonic pre-screening interview (ix) pregnant or prisoner: Pregnancy status will be determined via verbal confirmation during screening and documented in the eligibility checklist. (x) unable to eat the test product according to the regulations; (xi) participating in other clinical trial; (xii) any diagnosis or condition that renders the subject ineligible at the discretion of the PI and/or the study team
This trial is currently available in United States.
- Department of Neurosurgery and Brain and Spine and Faculty of USF Center for Microbiome Re-search, Microbiomes InstituteTampa, United StatesContact: Hariom Yadav, PhDTaking people
About the trial
What the trial wants to find out
This randomized placebo-controlled clinical study, called the LpD3.5 Intervention Study in Older Adults (LISA), aims to evaluate whether a heat-inactivated postbiotic of human origin (LpD3.5) can serve as a non-pharmacological intervention to reduce gut permeability and inflammation in older adults with mild cognitive impairment (MCI). The study will assess the effects of LpD3.5 supplementation on markers associated with gut health, inflammation, microbiome composition, and cognitive function.
Read full original descriptionShow less
Participants aged 60 years or older with clinically diagnosed MCI will receive either LpD3.5 capsules or placebo capsules for 60 days, followed by a 30-day follow-up period. Biological samples and clinical assessments will be collected to evaluate changes in gut permeability, inflammatory markers, microbiome characteristics, and cognitive outcomes. The findings from this study may provide insight into the potential role of postbiotics as a dietary intervention to improve gut health and related outcomes in older adults with MCI.
The 2 groups in the trial
- LpD3.5 groupExisting treatment, for comparison
This group will receive LpD3.5 (2 capsules per day) for a duration of 60 days with follow-up at 90-day.
Treatment: LpD3.5 and Placebo
- Placebo groupPlacebo, for comparison
They will receive a bottle of placebo capsules (2 capsules per day) for a duration of 60 days with follow-up at 90 days
Treatment: LpD3.5 and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Postbiotics Intervention to Improve Cognitive Function in Older Adults With Mild Cognitive Impairment (Phase 1)
- Plain-language title
- Heat-treated gut supplement LpD3.5 for older adults with mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 31 August 2026